Condition
Patients With Any Advanced Solid Tumors.
Estimated Enrollment: 18
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 2015-004511-21|2015/2329
Study First Received: August 2, 2016
Last Updated: August 4, 2016
Estimated Primary Completion Date: July 2021
Primary Outcome Measures:
MTD of Nintedanib
Sponsors and Collaborators:
Gustave Roussy, Cancer Campus, Grand Paris
Website Link: https://ClinicalTrials.gov/show/NCT02856425
